Amgen is lined up to copy 4 of the blockbuster drugs on this tracker, which earned $56.3B combined in 2025.
| Drug | Brand owner | Copy | US LOE | Amgen's stage | 2025 brand sales |
|---|---|---|---|---|---|
| Stelara Wezlana |
Johnson & Johnson | Biosimilar | 2025 | FDA-approved 31 Oct 2023; launched Jan 2025; interchangeable; first interchangeable biosimilar; its exclusivity as the only interchangeable ended 30 Apr 2025. First Stelara biosimilar on the US market | $6.1B |
| Keytruda | Merck | Biosimilar | 2028 | In clinical trials | $31.7B |
| Opdivo ABP 206 |
Bristol Myers Squibb | Biosimilar | 2028 | Filed with the FDA. Under FDA review | $10.1B |
| Ocrevus ABP 692 |
Roche | Biosimilar | 2029 | In clinical trials. Phase 3 results expected Jan 2027 | ≈$8.4B |
Company facts: SEC company tickers. Each drug page lists sources for these entries. Brand sales show the size of the market, not Amgen's share of it.
Amgen sells US copies of one of these drugs: Stelara (since Jan 2025). It also has applications filed for Opdivo; and copies in development for Keytruda and Ocrevus. Of the 70 makers we follow, 21 are lined up to copy more of the drugs on this tracker.
Copies with no confirmed US launch, by the earliest year each could reach the market: a settlement date where one is public, otherwise the brand's US exclusivity date. "Now" means that date has passed. Court rulings and new patents can move these.